Onco-Innovations Appoints Dr. Dennis Hall to Scientific & Clinical Advisory Board
Onco-Innovations (CBOE CA:ONCO) has appointed renowned chemist Dr. Dennis Hall to its Scientific and Clinical Advisory Board. Dr. Hall, a Professor of Chemistry at the University of Alberta and Tier 1 Canada Research Chair in Boron Chemistry, brings extensive expertise in organoboron chemistry, catalysis, and medicinal chemistry.
Dr. Hall's impressive credentials include over 175 peer-reviewed publications, 18,000+ citations, and numerous prestigious awards. He will provide strategic guidance on the company's R&D initiatives, particularly focusing on the development of PNKP Inhibitor Technology NP/A83 for oncology applications.
Onco-Innovations (CBOE CA:ONCO) ha nominato il rinomato chimico Dr. Dennis Hall nel suo Comitato Scientifico e Clinico Consultivo. Il Dr. Hall, Professore di Chimica presso l'Università di Alberta e titolare della cattedra Tier 1 Canada Research in Chimica del Boro, porta con sé una vasta esperienza in chimica organoboronica, catalisi e chimica medicinale.
Le impressionanti credenziali del Dr. Hall includono oltre 175 pubblicazioni peer-reviewed, più di 18.000 citazioni e numerosi premi prestigiosi. Fornirà una guida strategica alle iniziative di R&S della società, concentrandosi in particolare sullo sviluppo della tecnologia inibitrice PNKP NP/A83 per applicazioni oncologiche.
Onco-Innovations (CBOE CA:ONCO) ha designado al renombrado químico Dr. Dennis Hall para su Consejo Asesor Científico y Clínico. El Dr. Hall, Profesor de Química en la Universidad de Alberta y titular de la Cátedra de Investigación Canadá Nivel 1 en Química del Boro, aporta una amplia experiencia en química organoborónica, catálisis y química medicinal.
Las impresionantes credenciales del Dr. Hall incluyen más de 175 publicaciones revisadas por pares, más de 18,000 citas y numerosos premios prestigiosos. Brindará orientación estratégica en las iniciativas de I+D de la empresa, enfocándose especialmente en el desarrollo de la tecnología inhibidora de PNKP NP/A83 para aplicaciones oncológicas.
Onco-Innovations (CBOE CA:ONCO)는 저명한 화학자 Dr. Dennis Hall을 과학 및 임상 자문 위원회에 임명했습니다. Dr. Hall은 앨버타 대학교 화학 교수이자 캐나다 1급 연구석좌인 붕소 화학 분야 전문가로, 유기붕소 화학, 촉매 및 의약 화학에 대한 폭넓은 전문 지식을 보유하고 있습니다.
Dr. Hall의 뛰어난 경력에는 175편 이상의 동료 평가 논문, 18,000회 이상의 인용, 그리고 다수의 권위 있는 수상이 포함되어 있습니다. 그는 회사의 연구개발 이니셔티브에 전략적 조언을 제공하며, 특히 종양학 적용을 위한 PNKP 억제제 기술 NP/A83 개발에 집중할 예정입니다.
Onco-Innovations (CBOE CA:ONCO) a nommé le renommé chimiste Dr Dennis Hall à son Conseil consultatif scientifique et clinique. Le Dr Hall, professeur de chimie à l'Université de l'Alberta et titulaire de la chaire de recherche canadienne de niveau 1 en chimie du bore, apporte une expertise approfondie en chimie organoborée, catalyse et chimie médicinale.
Les impressionnantes références du Dr Hall comprennent plus de 175 publications évaluées par des pairs, plus de 18 000 citations et de nombreux prix prestigieux. Il fournira des conseils stratégiques sur les initiatives de R&D de l'entreprise, en se concentrant particulièrement sur le développement de la technologie inhibitrice PNKP NP/A83 pour des applications en oncologie.
Onco-Innovations (CBOE CA:ONCO) hat den renommierten Chemiker Dr. Dennis Hall in seinen Wissenschaftlichen und Klinischen Beirat berufen. Dr. Hall, Professor für Chemie an der Universität Alberta und Inhaber des Tier 1 Canada Research Chair für Bor-Chemie, bringt umfassende Expertise in Organobor-Chemie, Katalyse und medizinischer Chemie mit.
Dr. Halls beeindruckende Referenzen umfassen über 175 begutachtete Veröffentlichungen, mehr als 18.000 Zitationen und zahlreiche angesehene Auszeichnungen. Er wird strategische Beratung zu den F&E-Initiativen des Unternehmens geben, mit besonderem Fokus auf die Entwicklung der PNKP-Inhibitor-Technologie NP/A83 für onkologische Anwendungen.
- Addition of highly credentialed scientific expert with specific expertise in boron chemistry and drug discovery
- Strategic alignment with company's PNKP Inhibitor Technology development
- Enhanced scientific oversight for clinical translation plans
- None.
VANCOUVER, BC / ACCESS Newswire / July 21, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. Dennis Hall, Professor of Chemistry at the University of Alberta, to its Scientific and Clinical Advisory Board.
Dr. Hall is internationally recognized for his pioneering work in organoboron chemistry, catalysis, and medicinal chemistry, including the development of DNA repair inhibitors. He currently holds the Tier 1 Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery, and leads a multidisciplinary research team dedicated to the development of novel synthetic and biological applications of boron-containing compounds.[1]
With over 175 peer-reviewed publications, two books, and 15 book chapters, Dr. Hall's contributions span catalysis, heterocyclic chemistry, and medicinal chemistry. He has mentored more than 75 graduate students and postdoctoral fellows, and his work has been widely cited with over 18,000 citations and an h-index of 70.[2] Among his numerous accolades are the Arthur C. Cope Scholar Award (2024) from the American Chemical Society[3], the R. U. Lemieux Award (2021) from the Canadian Society for Chemistry[4], and a Killam Research Fellowship (2019-2021). He was elected a Fellow of the Royal Society of Canada in 2017. [5]
As part of his role, Dr. Hall will serve on the Scientific and Clinical Advisory Board and provide strategic advice to the Company on its Research and Development agenda, including clinical discovery, synthesis and manufacturing, pre-clinical testing, and clinical translation plans associated with Polynucleotide Kinase 3 Phosphatase (PNKP) Inhibitor Technology NP/A83. He will also collaborate with the Company's scientific and clinical leadership, as well as external partners, to advance oncology-focused innovations.
"Dr. Hall's appointment marks a significant step in bridging advanced synthetic chemistry with translational oncology. His expertise in boron-based drug discovery is uniquely aligned with our mission to develop precision therapies, and we look forward to leveraging his insight as we push our PNKP Inhibitor Technology toward the clinic," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the further development, potential commercialization and benefits of the Company's technologies, the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to further develop, prove out or commercialize its technologies, and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire
FAQ
Who is Dr. Dennis Hall and what is his role at Onco-Innovations (ONNVF)?
What are Dr. Dennis Hall's credentials and achievements?
How will Dr. Hall's appointment impact Onco-Innovations' drug development programs?
What is the significance of PNKP Inhibitor Technology for Onco-Innovations (ONNVF)?
